PDLI - PDLバイオファ―マ (PDL BioPharma Inc.) PDLバイオファ―マ

 PDLIのチャート


 PDLIの企業情報

symbol PDLI
会社名 PDL BioPharma Inc (PDLバイオファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   金融(Financials)
概要 事業概要 PDL・バイオファーマ(PDL BioPharma Inc.)はバイオテクノロジー医薬品及び医療機器業界の企業、製品、ロイヤリティ契約および債務のポートフォリオを取得・管理することにより、株主への利益還元を目指す。同社は2つの事業を運営する。収入生成資産セグメントは、米国およびその他の国で発行された特許のロイヤルティで構成され、「Queen et al.」特許とする抗体のヒト化、ノートおよびその他の長期債権、ロイヤルティ権・公正価値および持分投資をカバーする。同社の製品販売セグメントは、Tekturna、Tekturna HCT、RasilezおよびRasilez HCT(総称してNoden ProductsまたはTekturna)の売上高から構成される。同社は追加製品の取得に焦点を当てる。   PDLバイオファ―マは、米国のバイオ医薬品会社。腫瘍、免疫疾患用の治療薬の発見、研究開発に注力する。結腸がん治療薬「アバスチン」、転移性乳がん治療薬「ハ―セプチン」、喘息治療用抗体「ゾレア」、加齢黄斑変性症治療薬「ル―センティス」、抗慢性リウマチ薬「アクテムラ」の特許ライセンス契約を製薬会社と結び、ロイヤルティ―収入を得ている。   PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.
本社所在地 932 Southwood Boulevard Incline Village NV 89451 USA
代表者氏名 Dominique Monnet ドミニクモネ
代表者役職名 President 社長
電話番号 +1 775-832-8500
設立年月日 31594
市場名 NASDAQ National Market System
ipoyear 1992年
従業員数 14人
url www.pdl.com
nasdaq_url https://www.nasdaq.com/symbol/pdli
adr_tso
EBITDA EBITDA(百万ドル) 119.19400
終値(lastsale) 2.645
時価総額(marketcap) 384584007.745
時価総額 時価総額(百万ドル) 369.31700
売上高 売上高(百万ドル) 215.87800
企業価値(EV) 企業価値(EV)(百万ドル) 94.60900
当期純利益 当期純利益(百万ドル) -66.91000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 PDL BioPharma Inc revenues decreased 55% to $85.1M. Net loss totaled $110.7M vs. income of $67.7M. Revenues reflect Income generating assets segment decrease of 81% to $30M. Net loss reflects Gain on bargain purchase decrease from $6.3M (income) to $0K Selling and Marketing Expense increase of 76% to $10.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $0.43 to -$0.75.

 PDLIのテクニカル分析


 PDLIのニュース

   PDL BioPharma reports Q3 results (NASDAQ:PDLI)  2020/11/11 10:38:27 Seeking Alpha
PDL BioPharma (NASDAQ:PDLI): Q3 GAAP EPS of -$0.64. Revenue of $7.1M (-12.3% Y/Y) Press Release
   PDL BioPharma (NASDAQ:PDLI) Shares Down 5.2%  2020/10/21 10:36:45 Zolmax News
PDL BioPharma, Inc. (NASDAQ:PDLI)’s share price traded down 5.2% during trading on Monday . The company traded as low as $2.20 and last traded at $2.20. 755,649 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 1,182,237 shares. The stock had previously closed at $2.32. A number of […]
   Reviewing PDL BioPharma (NASDAQ:PDLI) & Acorda Therapeutics (NASDAQ:ACOR)  2020/10/20 10:04:42 Zolmax News
PDL BioPharma (NASDAQ:PDLI) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Earnings & Valuation This table compares PDL BioPharma and Acorda Therapeutics’ revenue, earnings per share […]
   PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital  2020/09/09 12:30:00 PR Newswire
INCLINE VILLAGE, Nev., Sept. 9, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA (collectively "Noden") to Stanley Capital. The total value of the…
   PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation  2020/08/31 13:00:00 PR Newswire
INCLINE VILLAGE, Nev., Aug. 31, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella®, Zalviso®, and Coflex® (collectively the "Royalties") to SWK…
   PDL BioPharma (NASDAQ:PDLI) Shares Down 5.2%  2020/10/21 10:36:45 Zolmax News
PDL BioPharma, Inc. (NASDAQ:PDLI)’s share price traded down 5.2% during trading on Monday . The company traded as low as $2.20 and last traded at $2.20. 755,649 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 1,182,237 shares. The stock had previously closed at $2.32. A number of […]
   Reviewing PDL BioPharma (NASDAQ:PDLI) & Acorda Therapeutics (NASDAQ:ACOR)  2020/10/20 10:04:42 Zolmax News
PDL BioPharma (NASDAQ:PDLI) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Earnings & Valuation This table compares PDL BioPharma and Acorda Therapeutics’ revenue, earnings per share […]
   PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital  2020/09/09 12:30:00 PR Newswire
INCLINE VILLAGE, Nev., Sept. 9, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA (collectively "Noden") to Stanley Capital. The total value of the…
   PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation  2020/08/31 13:00:00 PR Newswire
INCLINE VILLAGE, Nev., Aug. 31, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella®, Zalviso®, and Coflex® (collectively the "Royalties") to SWK…
   PDL BioPharma Announces Offer to Purchase Convertible Notes Due 2021 and 2024  2020/08/28 12:30:00 PR Newswire
INCLINE VILLAGE, Nev., Aug. 28, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that holders of its 2.75% Convertible Senior Notes due in December 2021 (the "2021 Notes") and in December 2024 (the "2024 Notes" and together with the 2021…
   PDL BioPharma (NASDAQ:PDLI) Shares Down 5.2%  2020/10/21 10:36:45 Zolmax News
PDL BioPharma, Inc. (NASDAQ:PDLI)’s share price traded down 5.2% during trading on Monday . The company traded as low as $2.20 and last traded at $2.20. 755,649 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 1,182,237 shares. The stock had previously closed at $2.32. A number of […]
   Reviewing PDL BioPharma (NASDAQ:PDLI) & Acorda Therapeutics (NASDAQ:ACOR)  2020/10/20 10:04:42 Zolmax News
PDL BioPharma (NASDAQ:PDLI) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations. Earnings & Valuation This table compares PDL BioPharma and Acorda Therapeutics’ revenue, earnings per share […]
   PDL BioPharma Completes Divestiture of the Noden Pharmaceutical Business to Stanley Capital  2020/09/09 12:30:00 PR Newswire
INCLINE VILLAGE, Nev., Sept. 9, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the closing of the sale of its wholly owned subsidiaries Noden Pharma DAC and Noden Pharma USA (collectively "Noden") to Stanley Capital. The total value of the…
   PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation  2020/08/31 13:00:00 PR Newswire
INCLINE VILLAGE, Nev., Aug. 31, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella®, Zalviso®, and Coflex® (collectively the "Royalties") to SWK…
   PDL BioPharma Announces Offer to Purchase Convertible Notes Due 2021 and 2024  2020/08/28 12:30:00 PR Newswire
INCLINE VILLAGE, Nev., Aug. 28, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that holders of its 2.75% Convertible Senior Notes due in December 2021 (the "2021 Notes") and in December 2024 (the "2024 Notes" and together with the 2021…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 PDLバイオファ―マ PDLI PDL BioPharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)